NASDAQ:MTSR Metsera (MTSR) Stock Price, News & Analysis $52.78 +0.26 (+0.50%) As of 10/15/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Metsera Stock (NASDAQ:MTSR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Metsera alerts:Sign Up Key Stats Today's Range$52.57▼$52.9850-Day Range$30.14▼$53.5852-Week Range$12.30▼$54.47Volume511,739 shsAverage Volume3.72 million shsMarket Capitalization$5.55 billionP/E RatioN/ADividend YieldN/APrice Target$55.75Consensus RatingHold Company Overview Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York. Read More Receive MTSR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Metsera and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MTSR Stock News HeadlinesPfizer is Locking in New Growth Through a New Acquisition (MTSR)Pfizer is undergoing a new acquisition, exposing it to the weight loss market and additional revenue growth potential, which isn't priced in yet.September 26, 2025 | marketbeat.comMetsera (MTSR): Evaluating Valuation After a 48% One-Month Share Price SurgeOctober 13 at 1:14 PM | finance.yahoo.comREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for yourself. Once you see what’s unfolding behind the scenes, you’ll understand why I rushed this interview and opportunity to you today. | Paradigm Press (Ad)Metsera, Inc. (MTSR) was downgraded to a Hold Rating at Wells FargoOctober 2, 2025 | theglobeandmail.comMetsera Announces Positive Phase 2b Trial ResultsOctober 2, 2025 | msn.comHealthy Returns: Pfizer's new obesity bet, Metsera, releases encouraging data on lead drugSeptember 30, 2025 | cnbc.comMetsera downgraded to Equal Weight from Overweight at Wells FargoSeptember 29, 2025 | msn.comMetsera's obesity drug shows promising weight loss in mid-stage trialsSeptember 29, 2025 | reuters.comSee More Headlines MTSR Stock Analysis - Frequently Asked Questions How have MTSR shares performed this year? Metsera's stock was trading at $29.50 at the start of the year. Since then, MTSR shares have increased by 78.9% and is now trading at $52.78. How were Metsera's earnings last quarter? Metsera Inc. (NASDAQ:MTSR) posted its quarterly earnings data on Monday, July, 28th. The company reported ($0.66) earnings per share for the quarter. When did Metsera IPO? Metsera (MTSR) raised $275 million in an initial public offering (IPO) on Friday, January 31st 2025. The company issued 15,277,778 shares at $18.00 per share. Who are Metsera's major shareholders? Top institutional investors of Metsera include Exchange Traded Concepts LLC (0.02%), Hamilton Lane Advisors LLC (0.01%) and Voya Investment Management LLC (0.01%). How do I buy shares of Metsera? Shares of MTSR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings7/28/2025Today10/15/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MTSR Previous SymbolNASDAQ:MTSR CIK2040807 WebN/A Phone(212) 784-6595FaxN/AEmployees81Year Founded2022Price Target and Rating Average Price Target for Metsera$55.75 High Price Target$62.00 Low Price Target$50.00 Potential Upside/Downside+5.6%Consensus RatingHold Rating Score (0-4)2.38 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio5.26 Quick Ratio5.26 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($2.46) per share Price / Book-21.46Miscellaneous Outstanding Shares105,060,000Free FloatN/AMarket Cap$5.55 billion OptionableN/A BetaN/A Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:MTSR) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredShots officially fired…Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the righ...Brownstone Research | SponsoredTrump’s “Smart Dollar” just went mainstream"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredTrump Devises the Death of the IRS ☠️Trump has just signed an executive order creating America's first-ever National Investment Fund — a game-chang...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Metsera Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Metsera With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
